Story perspectives

California's PBM Regulations Spark Controversy Over Drug Prices

5/25/2025

50 10

Summary

Story summary

California's Senate Bill 41 introduces regulations on PBMs, requiring licensing and rebate disclosures, but critics claim it may not reduce drug prices.
While PBMs secure savings for consumers, heightened regulation could hinder their efficiency.
Other states are considering similar regulations, raising fears of increased costs and diminished competition.
The FTC's lawsuit against PBMs faces criticism for its methodology and insufficient data.
Expanding government oversight of PBMs may negatively impact the healthcare system, according to critics.

1 of 1

Story summary

California's Senate Bill 41 introduces regulations on PBMs, requiring licensing and rebate disclosures, but critics claim it may not reduce drug prices.
While PBMs secure savings for consumers, heightened regulation could hinder their efficiency.
Other states are considering similar regulations, raising fears of increased costs and diminished competition.
The FTC's lawsuit against PBMs faces criticism for its methodology and insufficient data.
Expanding government oversight of PBMs may negatively impact the healthcare system, according to critics.